Related Experiment Video

Updated: Jun 20, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.0K

Tunlametinib: First Approval

Susan J Keam1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|July 21, 2024
PubMed

Insights

Tunlametinib, a MEK 1/2 inhibitor, received conditional approval in China for NRAS-mutated advanced melanoma. This milestone marks a significant step in treating solid tumors with RAS and RAF mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tunlametinib is an oral, selective mitogen-activated protein kinase kinase 1 and 2 (MEK 1/2) inhibitor.
  • It is developed for solid tumors harboring RAS and RAF mutations, such as melanoma, NSCLC, CRC, and NF1 plexiform neurofibromas.

Purpose of the Study:

  • To summarize the development milestones of tunlametinib.
  • To highlight its first conditional approval in China for specific cancer types.

Main Methods:

  • Review of development data and clinical trial outcomes.
  • Analysis of regulatory submission and approval process.

Main Results:

  • Conditional approval granted in China in March 2024.
  • Approval is for NRAS-mutated advanced melanoma patients post anti-PD-1/PD-L1 therapy, based on surrogate endpoints.

Conclusions:

  • Tunlametinib's approval represents a significant advancement in targeted therapy for RAS/RAF-mutated solid tumors.
  • This development paves the way for potential future approvals in other indications.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
504